Skip to content

AARD AARD Additional Paid-In Capital

Additional Paid-In Capital at other companies

Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$935.95M+37.5%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$1.53B+25.0%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$420.88M+29.5%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$1.51B+9.3%
Arvinas logo
ArvinasARVN
$2.15B+2.0%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$1.12B+7.8%

Other financials

Income statement

See full
Revenue-
Operating income-$22.5M-115%
Net income-$21.6M-132%
EPS (diluted)-$0.99-39.4%

Balance sheet

See full
Cash & equivalents$62.4M+136%
Total debt$336.0K-53.7%
Total equity$87.0M-42.3%
Total assets$98.6M-37.2%

Cash flow

See full
Operating cash flow-$18.9M-65.7%
CapEx--100%
Free cash flow-$16.8M-117%

Valuation

See full
Market cap$124.35M-58.6%
Enterprise value$62.25M-77.4%

Returns & leverage

See full
Return on equity-58.8%
Debt / equity0.0×
Current ratio8.1×-17.8×

Where this comes from

Reported directly by AARD in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: AARD’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about AARD's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AARD's additional paid-in capital?
AARD (AARD) reported additional paid-in capital of $224.48M in Q1 2026.
How has AARD's additional paid-in capital changed year-over-year?
AARD's additional paid-in capital increased by 2.8% year-over-year, from $218.28M to $224.48M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.